Ovarian cancer is one of the common malignant tumours of female reproductive organs. Due to early diagnosis difficulties and lack of effective treatment in the late stage, ovarian cancer has the highest mortality rate in female reproductive system malignancies. Therefore, finding reliable early diagnosis indicators and new therapeutic targets for ovarian cancer is an urgent problem to be solved. Chemokine (C‐X‐C motif) ligand 14 (CXCL14) is a small cytokine belonging to the CXC chemokine family, which has been found to possess multi‐effects in tumourigenesis and development. Here, we reported that CXCL14 was preferentially expressed in ovarian cancer. By analysing the TCGA database, we found that CXCL14 was highly expressed in advanced ovarian cancer patients and correlated with poor prognosis. In addition, the abnormal high CXCL14 levels were observed in serum and ovarian tissue of ovarian cancer patients by qRT‐PCR and ELISA. In vitro and in vivo experiments both confirmed that overexpression of CXCL14 promoted the ovarian cancer cell proliferation. Moreover, transfection of CXCL14 increased the phosphorylation level of signal transducer and activator of transcription 3 (STAT3), and administration of STAT3 inhibitor III inhibited the tumour‐promoting effects of CXCL14. Therefore, our study suggests that CXCL14 could be utilised as a novel adjunct biomarker for early diagnosis of ovarian cancer and provides new targets and ideas for the treatment of advanced ovarian cancer.

中文翻译：

---

CXCL14上调与不良的生存结果相关，并促进卵巢癌细胞增殖。

卵巢癌是女性生殖器官的常见恶性肿瘤之一。由于早期诊断的困难和后期缺乏有效的治疗方法，卵巢癌在女性生殖系统恶性肿瘤中死亡率最高。因此，寻找可靠的卵巢癌早期诊断指标和新的治疗靶点是亟待解决的问题。趋化因子（C‐X‐C基序）配体14（CXCL14）是属于CXC趋化因子家族的一种小型细胞因子，已被发现在肿瘤发生和发展中具有多种作用。在这里，我们报道了CXCL14在卵巢癌中优先表达。通过分析TCGA数据库，我们发现CXCL14在晚期卵巢癌患者中高表达，并与不良预后相关。此外，体外和体内实验均证实CXCL14的过度表达促进卵巢癌细胞的增殖。此外，CXCL14的转染增加了信号转导子和转录激活子3（STAT3）的磷酸化水平，而STAT3抑制剂III的给药抑制了CXCL14的促肿瘤作用。因此，我们的研究表明CXCL14可用作早期诊断卵巢癌的新型辅助生物标志物，并为晚期卵巢癌的治疗提供了新的靶标和思路。